ArticleFolia microbiologica2026
Escherichia marmotae: a multidrug-resistant opportunistic human pathogen - first clinical isolation in the Czech Republic.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Draft genomes of twoMicrobiology resource announcements · 2026Article
- From Cryptic Clade to Emerging Pathogen: Exploring the Evolutionary Divergence and Clinical Relevance ofMicroorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Escherichia comprises seven species, including Escherichia marmotae, described in 2015 from the feces of healthy Himalayan marmots (Marmota himalayana). This species exhibits atypical biochemical properties, such as negative lactose fermentation and indole production. The pathogenic potential of E. marmotae is demonstrated by its ability to invade epithelial cells and the presence of virulence genes. The first human infections with E. marmotae were recorded in Norway in 2021. This article describes the case of a 64-year-old man undergoing chemotherapy for urinary tract cancer, who was hospitalized with febrile neutropenia. An infection caused by E. marmotae and K. pneumoniae was detected. Laboratory diagnostics revealed a multidrug-resistant strain of E. coli producing KPC-type carbapenemase, subsequently identified as E. marmotae by MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry) and confirmed by 16S rRNA sequencing and whole genome sequencing. Biochemical tests indicated similarities to E. coli. Virulence analysis revealed the presence of genes typical of pathogenic strains of E. coli. This case report is the first documented instance of E. marmotae in the Czech Republic and highlights the difficulty of distinguishing this species from E. coli in routine diagnostics. Accurate identification requires advanced methods such as MALDI-TOF and sequencing analysis.
Indexed as
Identifiers
40423922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.